MA55799A - Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2 - Google Patents
Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2Info
- Publication number
- MA55799A MA55799A MA055799A MA55799A MA55799A MA 55799 A MA55799 A MA 55799A MA 055799 A MA055799 A MA 055799A MA 55799 A MA55799 A MA 55799A MA 55799 A MA55799 A MA 55799A
- Authority
- MA
- Morocco
- Prior art keywords
- aprmilast
- combination therapies
- therapies including
- tyk2 inhibitors
- tyk2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2019/029772 WO2020222773A1 (fr) | 2019-04-30 | 2019-04-30 | Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55799A true MA55799A (fr) | 2022-03-09 |
Family
ID=66476870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055799A MA55799A (fr) | 2019-04-30 | 2020-04-30 | Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2 |
Country Status (14)
| Country | Link |
|---|---|
| EP (2) | EP3962475A1 (fr) |
| JP (2) | JP2022537877A (fr) |
| KR (2) | KR20220002488A (fr) |
| CN (2) | CN114269336A (fr) |
| AU (2) | AU2019443366A1 (fr) |
| BR (2) | BR112021021809A2 (fr) |
| CA (2) | CA3138473A1 (fr) |
| CL (1) | CL2021002847A1 (fr) |
| CO (2) | CO2021015614A2 (fr) |
| IL (2) | IL287665A (fr) |
| MA (1) | MA55799A (fr) |
| MX (2) | MX2021013317A (fr) |
| SG (2) | SG11202112043PA (fr) |
| WO (2) | WO2020222773A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020222773A1 (fr) * | 2019-04-30 | 2020-11-05 | Celgene Corporation | Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2 |
| BR112023016614A2 (pt) | 2021-02-19 | 2023-11-07 | Sudo Biosciences Ltd | Inibidores de tyk2 e usos dos mesmos |
| EP4294807A1 (fr) | 2021-02-19 | 2023-12-27 | Sudo Biosciences Limited | Inhibiteurs de tyk2 et leurs utilisations |
| IL311624A (en) * | 2021-09-23 | 2024-05-01 | Bristol Myers Squibb Co | Methods for treating hair loss disorders with TYK2 inhibitors |
| KR20240111312A (ko) | 2021-10-25 | 2024-07-16 | 카이메라 쎄라퓨틱스 인코포레이티드 | Tyk2 분해제 및 이의 용도 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| GB0820819D0 (en) | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
| TW201040162A (en) * | 2009-05-06 | 2010-11-16 | Portola Pharm Inc | Inhibitors of JAK |
| CN103298794A (zh) | 2010-11-09 | 2013-09-11 | 塞尔卓姆有限公司 | 作为tyk2抑制剂的吡啶化合物及其氮杂类似物 |
| KR101889757B1 (ko) * | 2011-04-28 | 2018-08-20 | 셀진 코포레이션 | 자가 면역 및 염증 질환의 치료 및 관리를 위한 ｐｄｅ4 저해제를 이용한 방법 및 조성물 |
| AU2012362562B2 (en) | 2011-12-27 | 2017-11-02 | Amgen (Europe) GmbH | Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione |
| KR20140108594A (ko) | 2012-01-10 | 2014-09-11 | 에프. 호프만-라 로슈 아게 | 피리다진 아미드 화합물 및 syk 저해제로서의 이의 용도 |
| US9187453B2 (en) | 2012-03-28 | 2015-11-17 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| CA2875990A1 (fr) | 2012-05-24 | 2013-11-28 | Cellzome Limited | Analogues heterocyclyle de pyrimidine comme inhibiteurs de tyk2 |
| AU2013341195B2 (en) | 2012-11-08 | 2017-09-21 | Bristol-Myers Squibb Company | Alkyl amide-substituted pyrimidine compounds useful in the modulation of IL-12, IL-23 and/or IFNalpha |
| RS63328B1 (sr) * | 2012-11-08 | 2022-07-29 | Bristol Myers Squibb Co | Amidom-supstituisana heterociklična jedinjenja korisna kao modulatori il-12, il-23 i/ili ifn alfa odgovora |
| KR20150126618A (ko) * | 2013-03-14 | 2015-11-12 | 셀진 코포레이션 | 아프레밀라스트를 사용하는 건선성 관절염의 치료 |
| US20160159773A1 (en) | 2013-07-30 | 2016-06-09 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| CN105793245B (zh) | 2013-09-03 | 2018-03-20 | 萨勒姆有限公司 | 药物化合物 |
| AR094537A1 (es) | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| JP6458038B2 (ja) | 2013-12-10 | 2019-01-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物 |
| WO2015091584A1 (fr) | 2013-12-18 | 2015-06-25 | F. Hoffmann-La Roche Ag | Composés de thiazolopyridine, compositions et leur utilisation comme inhibiteurs de la kinase tyk2 |
| US9834548B2 (en) * | 2014-02-14 | 2017-12-05 | Portola Pharmaceuticals, Inc. | Pyridazine compounds as JAK inhibitors |
| ES2921874T3 (es) | 2014-02-28 | 2022-09-01 | Nimbus Lakshmi Inc | Inhibidores de TYK2 y usos de los mismos |
| ES2749433T3 (es) | 2014-06-23 | 2020-03-20 | Celgene Corp | Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática |
| US10092541B2 (en) * | 2014-08-15 | 2018-10-09 | Celgene Corporation | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
| NO2721710T3 (fr) | 2014-08-21 | 2018-03-31 | ||
| WO2016047678A1 (fr) | 2014-09-25 | 2016-03-31 | 武田薬品工業株式会社 | Composé hétérocyclique |
| US20160251376A1 (en) | 2015-02-27 | 2016-09-01 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| US10023571B2 (en) | 2015-09-02 | 2018-07-17 | Nimbus Lakshimi, Inc. | TYK2 inhibitors and uses thereof |
| RS60261B1 (sr) | 2016-02-24 | 2020-06-30 | Pfizer | Pirazolo[1,5-a]pirazin-4-il derivativi kao jak-inhibitori |
| EP3523305B1 (fr) | 2016-10-07 | 2021-12-08 | Bristol-Myers Squibb Company | Composés imidazopyridazine utiles en tant que modulateurs de réponses il-12, il-23 et/ou ifn alpha |
| AU2017342464B2 (en) | 2016-10-14 | 2021-09-16 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
| WO2018075937A1 (fr) | 2016-10-21 | 2018-04-26 | Nimbus Lakshmi, Inc. | Inhibiteurs de tyk2 et leurs utilisations |
| ES2895107T3 (es) | 2016-10-28 | 2022-02-17 | Bristol Myers Squibb Co | Compuestos heterobicíclicos útiles como moduladores de las respuestas de IL-12, IL-23 y/o IFN alfa |
| WO2018093968A1 (fr) | 2016-11-17 | 2018-05-24 | Bristol-Myers Squibb Company | Modulateurs d'imidazopyridazine d'il-12, il-23 et/ou ifn-alpha |
| GB2562702B (en) | 2017-03-06 | 2022-05-18 | Linear Shaped Ltd | Frame and linear shaped charge |
| EP4338802A3 (fr) * | 2017-03-08 | 2024-09-04 | Takeda Pharmaceutical Company Limited | Inhibiteurs de tyk2, utilisations et procédés de production associés |
| WO2020222773A1 (fr) * | 2019-04-30 | 2020-11-05 | Celgene Corporation | Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2 |
-
2019
- 2019-04-30 WO PCT/US2019/029772 patent/WO2020222773A1/fr unknown
- 2019-04-30 CA CA3138473A patent/CA3138473A1/fr active Pending
- 2019-04-30 SG SG11202112043PA patent/SG11202112043PA/en unknown
- 2019-04-30 JP JP2021564469A patent/JP2022537877A/ja not_active Abandoned
- 2019-04-30 KR KR1020217038511A patent/KR20220002488A/ko unknown
- 2019-04-30 CN CN201980097711.6A patent/CN114269336A/zh active Pending
- 2019-04-30 IL IL287665A patent/IL287665A/en unknown
- 2019-04-30 AU AU2019443366A patent/AU2019443366A1/en not_active Abandoned
- 2019-04-30 MX MX2021013317A patent/MX2021013317A/es unknown
- 2019-04-30 EP EP19723291.1A patent/EP3962475A1/fr active Pending
- 2019-04-30 BR BR112021021809A patent/BR112021021809A2/pt unknown
-
2020
- 2020-04-30 WO PCT/US2020/030608 patent/WO2020223431A1/fr unknown
- 2020-04-30 MA MA055799A patent/MA55799A/fr unknown
- 2020-04-30 KR KR1020217038512A patent/KR20220002489A/ko unknown
- 2020-04-30 BR BR112021021826A patent/BR112021021826A8/pt unknown
- 2020-04-30 CA CA3138686A patent/CA3138686A1/fr active Pending
- 2020-04-30 EP EP20725978.9A patent/EP3962476A1/fr active Pending
- 2020-04-30 MX MX2021013318A patent/MX2021013318A/es unknown
- 2020-04-30 SG SG11202112018YA patent/SG11202112018YA/en unknown
- 2020-04-30 JP JP2021564471A patent/JP7453251B2/ja active Active
- 2020-04-30 CN CN202080046457.XA patent/CN114206333A/zh active Pending
- 2020-04-30 AU AU2020266143A patent/AU2020266143A1/en active Pending
-
2021
- 2021-10-28 IL IL287670A patent/IL287670A/en unknown
- 2021-10-29 CL CL2021002847A patent/CL2021002847A1/es unknown
- 2021-11-22 CO CONC2021/0015614A patent/CO2021015614A2/es unknown
- 2021-11-22 CO CONC2021/0015622A patent/CO2021015622A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020223431A1 (fr) | 2020-11-05 |
| EP3962476A1 (fr) | 2022-03-09 |
| EP3962475A1 (fr) | 2022-03-09 |
| BR112021021826A8 (pt) | 2022-06-21 |
| BR112021021809A2 (pt) | 2022-01-04 |
| JP2022537878A (ja) | 2022-08-31 |
| CA3138686A1 (fr) | 2020-11-05 |
| IL287670A (en) | 2021-12-01 |
| CO2021015614A2 (es) | 2021-12-10 |
| WO2020222773A1 (fr) | 2020-11-05 |
| SG11202112018YA (en) | 2021-11-29 |
| CO2021015622A2 (es) | 2022-02-28 |
| JP2022537877A (ja) | 2022-08-31 |
| MX2021013317A (es) | 2022-01-18 |
| CA3138473A1 (fr) | 2020-11-05 |
| MX2021013318A (es) | 2022-01-31 |
| IL287665A (en) | 2022-07-01 |
| CN114269336A (zh) | 2022-04-01 |
| SG11202112043PA (en) | 2021-11-29 |
| BR112021021826A2 (pt) | 2022-01-04 |
| JP7453251B2 (ja) | 2024-03-19 |
| CL2021002847A1 (es) | 2022-07-22 |
| KR20220002489A (ko) | 2022-01-06 |
| KR20220002488A (ko) | 2022-01-06 |
| CN114206333A (zh) | 2022-03-18 |
| AU2020266143A1 (en) | 2021-12-02 |
| AU2019443366A1 (en) | 2021-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55799A (fr) | Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2 | |
| SG11202104017VA (en) | Tyk2 inhibitors and uses thereof | |
| GB201909190D0 (en) | Therapeutic agents | |
| MA44890A (fr) | Compositions comprenant des souches bactériennes | |
| GB201909194D0 (en) | Therapeutic agents | |
| GB201909191D0 (en) | Therapeutic agents | |
| MA46716A (fr) | Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie | |
| IL282090A (en) | tyk2 inhibitors and uses thereof | |
| IL276609A (en) | Combined treatment with epilimod and glutamatergic factors | |
| IL286248A (en) | tyk2 inhibitors and their use | |
| PH12021551282A1 (en) | Radioimmunoconjugates and checkpoint inhibitor combination therapy | |
| IL279810A (en) | Heteroaryl-converted sulfonamide compounds and their use as medicinal agents | |
| BR112017025998A2 (pt) | inibidor de eixo igfbp3/tmem219, composição farmacêutica para uso no tratamento e/ou prevenção de diabetes, método para identificar um indivíduo em risco de desenvolver diabetes tipo 1 e/ou tipo 2 ou para monitorar a resposta a um tratamento terapêutico em um indivíduo e kit | |
| MA47074A (fr) | Formes pharmaceutiques comprenant des inhibiteurs de canaux de task-1 et task-3 et leur utilisation pour le traitement des troubles respiratoires | |
| MA52165A (fr) | Inhibiteurs sélectifs de l'isoforme tgfbeta1 et utilisation associée | |
| GB201902277D0 (en) | Therapeutic agents | |
| ZA202100092B (en) | Modified cas9 protein and use thereof | |
| MA55816A (fr) | Combinaisons thérapeutiques comprenant des immunoconjugués anti-cd123 | |
| GB201918541D0 (en) | Therapeutic compounds and their use | |
| GB201906804D0 (en) | Therapeutic agents | |
| PT3937949T (pt) | Fitoecdisonas e seus derivados para utilização no tratamento da alteração da função respiratória | |
| MA55781A (fr) | Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2 | |
| IL289531A (en) | cd38 binding agents and uses thereof | |
| IL288828A (en) | Binding factors - cd38 and their use | |
| GB201905520D0 (en) | Compounds and their therapeutic use |